Financials in USD. Standardized financial statements.
A compact view of how Universe Pharmaceuticals Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue? | $17.86M | $23.02M | $32.31M | $40.14M | $47.98M | $30.70M | $33.23M | $28.51M |
| Revenue Growth? | -22.4% | -28.7% | -19.5% | -16.3% | +56.3% | -7.6% | +16.5% | 0.0% |
| Cost of Revenue? | $11.56M | $16.95M | $21.99M | $18.25M | $22.66M | $16.61M | $19.82M | $15.11M |
| Gross Profit? | $6.30M | $6.07M | $10.32M | $21.89M | $25.33M | $14.09M | $13.41M | $13.41M |
| Gross Margin? | +35.3% | +26.4% | +31.9% | +54.5% | +52.8% | +45.9% | +40.3% | +47.0% |
| Operating Expenses? | $9.22M | $14.09M | $13.84M | $28.91M | $11.74M | $3.74M | $3.36M | $3.65M |
| Operating Income? | -$2.92M | -$8.02M | -$3.53M | -$7.02M | $13.59M | $10.25M | $9.75M | $9.66M |
| EBITDA? | -$2.92M | -$7.36M | -$3.18M | -$6.40M | $14.20M | $10.61M | $10.17M | $10.11M |
| Income Before Tax | -$3.67M | -$8.12M | -$3.94M | -$7.98M | $13.65M | $10.10M | $9.65M | $9.52M |
| Income Tax Expense | $0 | $606,704 | $2.25M | $752,419 | $2.36M | $2.54M | $2.10M | $1.92M |
| Net Income? | -$3.67M | -$8.73M | -$6.16M | -$8.74M | $11.32M | $7.56M | $7.55M | $7.60M |
| EPS? | $-1055.75 | $-1436.12 | $-1040.53 | $-1475.02 | $2147.18 | $1295.70 | $1294.54 | $1303.36 |
| Diluted EPS? | $-1055.75 | $-1436.12 | $-1040.53 | $-1475.02 | $2147.18 | $1295.70 | $1294.54 | $1303.36 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality